Aberrant Cytokine Signaling in Leukemia

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2007 Oct 16

PMID 17934482

Citations 52

Authors

R A Van Etten

Affiliations

Soon will be listed here.

Abstract

Abnormalities of cytokine and growth factor signaling pathways are characteristic of all forms of leukemia: lymphoid and myeloid, acute and chronic. In normal hematopoietic cells, cytokines provide the stimulus for proliferation, survival, self-renewal, differentiation and functional activation. In leukemic cells, these pathways are usurped to subserve critical parts of the malignant program. In this review, our current knowledge of leukemic cell cytokine signaling will be summarized, and some speculations on the significance and implications of these insights will be advanced. A better understanding of aberrant cytokine signaling in leukemia should provide additional targets for the rational therapy of these diseases.

Citing Articles

Selected Elements of the Tumor Microenvironment (MMP-2, MMP-7, TIMP-2, CXCL-9, CXCL-10) in the Serum of Pediatric Patients with Acute Lymphoblastic Leukemia.

Kaczorowska A, Miekus-Purwin N, Owczarzak A, Gabrych A, Wojciechowska M, Irga-Jaworska N Cells. 2025; 14(4).

PMID: 39996769 PMC: 11854448. DOI: 10.3390/cells14040297.

Autoinflammation in patients with leukocytic CBL loss of heterozygosity is caused by constitutive ERK-mediated monocyte activation.

Bohlen J, Bagaric I, Vatovec T, Ogishi M, Ahmed S, Cederholm A J Clin Invest. 2024; 134(20).

PMID: 39403923 PMC: 11475086. DOI: 10.1172/JCI181604.

Protein arginine methyltransferase 2 controls inflammatory signaling in acute myeloid leukemia.

Sauter C, Morin T, Guidez F, Simonet J, Fournier C, Row C Commun Biol. 2024; 7(1):753.

PMID: 38902349 PMC: 11190286. DOI: 10.1038/s42003-024-06453-6.

Protective Role of the Podocyte IL-15 / STAT5 Pathway in Focal Segmental Glomerulosclerosis.

Niasse A, Louis K, Lenoir O, Schwarz C, Xu X, Couturier A Kidney Int Rep. 2024; 9(4):1093-1106.

PMID: 38765560 PMC: 11101713. DOI: 10.1016/j.ekir.2024.01.010.

N-Ethyl-N-Nitrosourea Induced Leukaemia in a Mouse Model: Protective Effect of Icaritin via Inhibition of IL-6/JAK2/STAT3 Pathway Causes Apoptosis.

Hou X, Han Y, Hirad A, Alarfaj A, Liu L J Inflamm Res. 2024; 17:777-790.

PMID: 38344310 PMC: 10859094. DOI: 10.2147/JIR.S441755.

References

Van Etten R . Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res. 2004; 28 Suppl 1:S21-8. DOI: 10.1016/j.leukres.2003.10.005. View

Chan I, Kutok J, Williams I, Cohen S, Kelly L, Shigematsu H . Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest. 2004; 113(4):528-38. PMC: 338267. DOI: 10.1172/JCI20476. View

Golub T, Goga A, Barker G, Afar D, McLaughlin J, Bohlander S . Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol. 1996; 16(8):4107-16. PMC: 231407. DOI: 10.1128/MCB.16.8.4107. View

Pikman Y, Lee B, Mercher T, McDowell E, Ebert B, Gozo M . MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3(7):e270. PMC: 1502153. DOI: 10.1371/journal.pmed.0030270. View

Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng C . Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol. 2004; 24(18):8037-47. PMC: 515028. DOI: 10.1128/MCB.24.18.8037-8047.2004. View

Van Etten R . Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol. 1999; 9(5):179-86. DOI: 10.1016/s0962-8924(99)01549-4. View

Cools J, DeAngelo D, Gotlib J, Stover E, Legare R, Cortes J . A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348(13):1201-14. DOI: 10.1056/NEJMoa025217. View

Pulford K, Lamant L, Espinos E, Jiang Q, Xue L, Turturro F . The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci. 2004; 61(23):2939-53. DOI: 10.1007/s00018-004-4275-9. View

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

10.

Smith K, Yacobi R, Van Etten R . Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell. 2003; 12(1):27-37. PMC: 7128750. DOI: 10.1016/s1097-2765(03)00274-0. View

11.

Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse J, Capiod J, Delobel J . STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood. 1996; 87(5):1692-7. View

12.

Grandage V, Gale R, Linch D, Khwaja A . PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia. 2005; 19(4):586-94. DOI: 10.1038/sj.leu.2403653. View

13.

Huntly B, Shigematsu H, Deguchi K, Lee B, Mizuno S, Duclos N . MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004; 6(6):587-96. DOI: 10.1016/j.ccr.2004.10.015. View

14.

Gilliland D, Tallman M . Focus on acute leukemias. Cancer Cell. 2002; 1(5):417-20. DOI: 10.1016/s1535-6108(02)00081-8. View

15.

Samanta A, Lin H, Sun T, Kantarjian H, Arlinghaus R . Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 2006; 66(13):6468-72. DOI: 10.1158/0008-5472.CAN-06-0025. View

16.

Million R, Aster J, Gilliland D, Van Etten R . The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood. 2002; 99(12):4568-77. DOI: 10.1182/blood-2001-12-0244. View

17.

Gururajan M, Dasu T, Shahidain S, Jennings C, Robertson D, Rangnekar V . Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J Immunol. 2006; 178(1):111-21. DOI: 10.4049/jimmunol.178.1.111. View

18.

Van Etten R . Models of chronic myeloid leukemia. Curr Oncol Rep. 2001; 3(3):228-37. DOI: 10.1007/s11912-001-0055-y. View

19.

James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

20.

Weinstein I . Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297(5578):63-4. DOI: 10.1126/science.1073096. View